Clinical trials
Graft Vs Host Disease clinical trials
Below are recruiting graft vs host disease clinical trials, each written for real people, not researchers. We’re tracking 31 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06649201Recruiting
Study of vaginal health after stem cell transplant
This study looks at how stem cell transplants affect the vagina, especially if you develop a condition called graft-versus-host disease (GVHD). Researchers will examine the vagina and test its natural germs (microbiome) to better understand and possibly improve treatment.
Cleveland, OhioAges 18–70 - NCT06450925RecruitingPhase 2
Vitamin A supplement for stem cell transplant patients
This study tests whether giving vitamin A by mouth to adults before and after a stem cell transplant can help their recovery. The goal is to see if it reduces complications and improves overall outcomes.
Tampa, FloridaAges 18 years+ - NCT07166848Enrolling by invitation
Electrical stimulation study for dry eye from graft vs. host disease
This trial tests if gentle electrical stimulation around the eye can help relieve dry eye symptoms caused by chronic graft versus host disease (a complication after a stem cell or bone marrow transplant). It is for people with moderate to severe dry eye who have not had recent eye surgeries or certain other eye problems.
Boston, MassachusettsAges 18–75 - NCT04700657Recruiting
Study dryness patterns in eye graft-vs-host disease
This study looks at how common and how severe corneal nerve-related dryness is in people with chronic graft-vs-host disease (GVHD) after a stem cell transplant. It may help doctors understand which eye problems are most typical and how best to recognize them early.
Indianapolis, IndianaAges 18 years+ - NCT00092235Recruiting
Understanding chronic graft-versus-host disease outcomes
This study follows patients who have had a stem cell transplant and developed chronic graft-versus-host disease (a condition where transplanted cells attack the body). Researchers will track your symptoms and collect blood samples to understand what affects how well patients do over time.
Bethesda, MarylandAges 1–120 - NCT07725263Recruiting
Low-dose antifungal for kids with low white blood cells
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent serious fungal infections in children whose immune system is weak after cancer treatment or a stem cell transplant. It's for kids aged 3 to 17 who are at high risk for these infections.
Haikou, HainanAges 3–17 - NCT04337515Recruiting
Study of a new method to prepare stem cell transplants
This feasibility study tests a technique called CLINIMACS to reduce certain immune cells (alpha/beta T-cells) before a stem cell transplant. It may help make the transplant safer and better controlled, but this is an early-stage feasibility test.
San Francisco, CaliforniaAges Up to 30 years - NCT04380740RecruitingPhase 2
Longer vs shorter abatacept doses to prevent graft-versus-host disease
This trial tests whether giving abatacept for a longer or shorter time can better prevent graft-versus-host disease (a common complication after a stem cell transplant). If you’re having a planned unrelated donor transplant, the results may help reduce the risk or severity of transplant-related immune problems.
Duarte, CaliforniaAges 2 years+ - NCT04678401RecruitingPhase 1
Trial tests transplant using a half-matched donor for high-risk leukemia
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Boston, MassachusettsAges 18–75 - NCT05170347Recruiting
Study of graft-versus-host disease after bone marrow transplant
This study follows people after an allogeneic bone marrow transplant to understand a complication called graft-versus-host disease. If you can attend follow-up visits, your experience and samples may be compared with a family control to look for differences.
Hong KongAges 18 years+ - NCT05236062Recruiting
Exercise during steroid treatment for GVHD
This study looks at whether doing moderate-to-vigorous exercise can reduce complications from corticosteroids in people with newly diagnosed GVHD. It may help your body tolerate steroids better, while checking exercise safety during treatment.
Boston, MassachusettsAges 18 years+ - NCT05333367Recruiting
Study of how a light treatment causes immune cell death
This trial looks at how “extracorporeal photochemotherapy” (a light-based treatment done outside the body) works at the cellular level. It may help improve treatment and control for people dealing with immune reactions after transplant or certain blood/skin conditions.
BesançonAges 18–85 - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT06568328RecruitingPhase 1
Experimental cell therapy for severe graft-versus-host disease
This trial tests a new immune cell treatment for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard medications like ruxolitinib. The goal is to see if these special cells can calm the immune attack and help manage symptoms.
Fuzhou, FujianAges 1–70 - NCT06681922RecruitingPhase 1/Phase 2
A new combination to prevent graft-versus-host disease after stem cell transplant
This study tests a combination of three drugs—high-dose cyclophosphamide, bortezomib, and abatacept—after a donor stem cell transplant to see if they can better prevent graft-versus-host disease (a condition where donor cells attack the body).
Lake Success, New YorkAges 18 years+ - NCT06824103RecruitingPhase 4
Study of ruxolitinib for chronic graft-versus-host disease in China
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
Hefei, AnhuiAges 12–100 - NCT07184853Recruiting
Ruxolitinib with etanercept vs ruxolitinib for severe GVHD
This trial tests whether adding etanercept to ruxolitinib works better than ruxolitinib alone for severe graft-versus-host disease (GVHD) that has not responded to steroids. GVHD is a common complication after a stem cell transplant where donor cells attack the patient's body.
Hangzhou, ZhejiangAges 12–70 - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Miami, FloridaAges 18–120 - NCT07364617RecruitingPhase 2
Fecal transplant for steroid-resistant gut GVHD
This study tests if a fecal transplant (transferring healthy bacteria from a donor's stool into your gut) can help people with severe gut graft-versus-host disease that hasn't responded to steroids. It's for patients who have had a stem cell transplant and now have ongoing, severe gut symptoms.
TaoyuanAges Any age - NCT07365696Recruiting
Fatigue and brain fog after stem cell transplant
This trial looks at the causes of fatigue and cognitive problems (like memory or concentration issues) after a stem cell transplant. It uses old PET scans to study possible damage in the brain.
StockholmAges 20–75 - NCT00106925Recruiting
Long-term follow-up for people after stem cell transplant
This study follows people who are at least 3 years out from their first stem cell transplant to learn how they are doing long term. It may help improve future transplant care by tracking outcomes over time.
Bethesda, MarylandAges 7–80 - NCT07006506RecruitingPhase 2
Belumosudil to prevent graft-versus-host disease after transplant
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
Basking Ridge, New JerseyAges 18 years+ - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07606703RecruitingPhase 2
Madecassoside for Hardened Skin After Bone Marrow Transplant
This trial tests whether a plant-derived medicine called madecassoside can help treat sclerotic chronic graft-versus-host disease (a hardening and tightening of the skin that sometimes happens after bone marrow transplant). You would take tablets and be monitored to see if your skin condition improves.
Wuhan, HubeiAges 14–65
Hear when a new Graft Vs Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Graft Vs Host Disease trials by city
Studies with a site in or near these metro areas.
Graft Vs Host Disease trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for graft vs host disease?
- Yes. Clin2 currently lists 31 recruiting graft vs host disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a graft vs host disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a graft vs host disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.